

TRANSGENOMIC INC
Form 10-Q/A
June 30, 2005
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2004

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 000-30975

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

Delaware
(State or other jurisdiction of
incorporation or organization)
12325 Emmet Street, Omaha, Nebraska
(Address of principal executive offices)

911789357
(I.R.S. Employer
Identification No.)
68164
(Zip Code)

(402) 452-5400

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past

90 days. Yes No

Indicate by check mark whether the registrant is accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes No

As of November 15, 2004, the number of shares of common stock outstanding was 29,070,651.

Table of Contents

Explanatory Note

We are amending our quarterly report on Form 10-Q for the quarterly period ended September 30, 2004 (Form 10-Q) for certain adjustments that are required to appropriately report cash flows from operating and investing activities in the condensed consolidated statements of cash flows included in Part I, Item 1 herein and related cash flow disclosures included in Part I, Item 2. These restatements are discussed in Note M to the condensed consolidated financial statements and result only in a reclassification of certain items within the condensed consolidated statements of cash flows. They have no effect on the net change in cash and cash equivalents for any period reported or any other line item in the condensed consolidated financial statements. Except to the extent affected by the correction of this error, we have made no other changes to our Form 10-Q.

Table of Contents

TRANSGENOMIC INC.

INDEX

	<u>Page No.</u>
PART I.	
<u>FINANCIAL INFORMATION</u>	1
Item 1.	
<u>Financial Statements</u>	1
<u>Condensed Consolidated Balance Sheets as of September 30, 2004 and December 31, 2003</u>	1
<u>Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2004 and 2003</u>	2
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2004 (restated) and 2003 (restated)</u>	3
<u>Notes to Condensed Consolidated Financial Statements</u>	4
Item 2.	
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	12
Item 4.	
<u>Controls and Procedures</u>	20
PART II	
<u>OTHER INFORMATION</u>	21
Item 6.	
<u>Exhibits</u>	21
<u>Signatures</u>	23

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Financial Statements****Transgenomic, Inc. and Subsidiaries****Condensed Consolidated Balance Sheets (Unaudited)**

(In thousands except share and per share data)

	September 30,	December 31,
	2004	2003
	<u> </u>	<u> </u>
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 1,125	\$ 1,241
Accounts receivable net	10,306	10,877
Inventories	7,193	10,584
Prepaid expenses and other current assets	1,700	1,676
	<u> </u>	<u> </u>
Total Current Assets	20,324	24,378
Property and Equipment		
Land and buildings	2,263	2,239
Equipment	21,581	20,362
Furniture and fixtures	9,092	9,054
	<u> </u>	<u> </u>
Total property and equipment	32,936	31,655
Less: accumulated depreciation	18,032	12,951
	<u> </u>	<u> </u>
Net property and equipment	14,904	18,704
Goodwill	638	10,503
Intangible and other assets	5,811	3,721
	<u> </u>	<u> </u>
Total Assets	\$ 41,677	\$ 57,306
	<u> </u>	<u> </u>
LIABILITIES AND STOCKHOLDERS EQUITY		
Current Liabilities		
Accounts payable	\$ 3,651	\$ 3,580
Other accrued expenses	4,451	3,874
Accrued compensation	1,199	959
Line of credit	7,906	2,142
Current portion of long-term debt	975	1,693
	<u> </u>	<u> </u>
Total current liabilities	18,182	12,248
Long-term Liabilities		
Long-term debt	2,306	
	<u> </u>	<u> </u>

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

Total liabilities	20,488	12,248
Commitments and Contingencies (Note G)		
Stockholders Equity		
Preferred stock \$.01 par value, 15,000,000 shares authorized, none outstanding		
Common stock \$.01 par value, 60,000,000 shares authorized, 28,887,334 and 28,119,122 issued in 2004 and 2003, respectively	296	286
Additional paid-in capital	119,430	115,904
Accumulated other comprehensive income (loss)	1,626	1,597
Accumulated deficit	(100,163)	(72,729)
	<u>21,189</u>	<u>45,058</u>
Total stockholders equity	21,189	45,058
	<u>21,189</u>	<u>45,058</u>
Total liabilities and stockholders equity	\$ 41,677	\$ 57,306
	<u>\$ 41,677</u>	<u>\$ 57,306</u>

The accompanying notes are an integral part of these financial statements.

Table of Contents**Transgenomic, Inc. and Subsidiaries****Condensed Consolidated Statements of Operations (Unaudited)****(In thousands except share and per share data)**

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2004	2003	2004	2003
Net sales	\$ 8,194	\$ 7,537	\$ 25,834	\$ 25,521
Cost of goods sold	6,857	6,762	18,484	18,500
Gross profit	1,337	775	7,350	7,021
Operating expenses:				
Selling, general and administrative	4,353	4,331	12,866	13,239
Research and development	1,743	2,411	5,344	7,098
Restructuring Charges (Note K)				738
Impairment Charges (Note E)			11,964	
	6,096	6,742	30,174	21,075
Loss from operations	(4,759)	(5,967)	(22,824)	(14,054)
Other income (expense):				
Interest and investment income/(loss)	(345)	2	(371)	48
Interest expense	(378)	(98)	(1,313)	(191)
Loss on debt extinguishment (Note J)	(2,859)		(2,859)	
Other, net	(100)	(9)	(161)	(118)
	(3,682)	(105)	(4,704)	(261)
Loss before income taxes	(8,441)	(6,072)	(27,528)	(14,315)
Current income tax expense (benefit)	1	25	(94)	49
Net loss	\$ (8,442)	\$ (6,097)	\$ (27,434)	\$ (14,364)
Basic and diluted weighted average shares outstanding	29,077,789	24,176,567	28,951,230	23,741,120
Net loss per common share basic and diluted	\$ (0.29)	\$ (0.25)	\$ (0.95)	\$ (0.61)

The accompanying notes are an integral part of these financial statements.

Table of Contents**Transgenomic, Inc. and Subsidiaries****Condensed Consolidated Statement of Cash Flows (Unaudited)**

(In thousands)

	Nine Months Ended	
	September 30,	
	2004	2003
	(As restated, see Note M)	
Cash Flows from Operating Activities		
Net loss	\$ (27,434)	\$ (14,364)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Depreciation and amortization	3,607	3,312
Impairment charges (Note E)	11,964	
Loss on Debt Extinguishment	2,859	
Non-cash financing charges	759	364
Other	382	140
Changes in operating assets and liabilities:		
Purchase of trading securities		(1,565)
Proceeds from sale of trading securities		1,519
Accounts receivable	(2,469)	1,482
Inventories	819	1,909
Prepaid expenses and other current assets	(69)	(192)
Accounts payable	100	(158)
Accrued expenses and other current liabilities	774	(1,865)
Net cash flows from operating activities	(8,708)	(9,418)
Cash Flows from Investing Activities		
Purchase of property and equipment	(1,250)	(5,646)
Proceeds from the maturities and sale of available for sale securities	2,768	3,612
Change in other assets	26	(152)
Net cash flows from investing activities	1,544	(2,186)
Cash Flows from Financing Activities		
Issuance of common stock and common stock warrants	67	1,787
Proceeds from long-term debt	2,750	
Payment of long-term debt	(1,729)	
Line of credit	6,097	1,371
Net cash flows from financing activities	7,185	3,158
Effect of foreign currency exchange rates on cash	(137)	(148)
Net change in cash and cash equivalents	(116)	(8,594)
Cash and cash equivalents at beginning of period	1,241	9,735
Cash and cash equivalents at end of period	\$ 1,125	\$ 1,141
Non-cash Items:		
Available for sale securities acquired for goods and services	\$ 3,137	\$ 425



The accompanying notes are an integral part of these financial statements.

Table of Contents

Transgenomic, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In thousands except share and per share data)

A. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements of Transgenomic, Inc. and Subsidiaries (the Company) have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. In the opinion of management of the Company, all adjustments (consisting of only normal and recurring accruals) have been made to present fairly the financial positions, the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2004 and 2003 are not necessarily indicative of the results to be expected for the full year. Although the Company believes that the disclosures are adequate to make the information presented not misleading, these financial statements should be read in conjunction with the consolidated financial statements for the period ended December 31, 2003, that are included in the Company's 2004 Annual Report on Form 10-K/A-2.

The Company has experienced recurring net losses and had an accumulated deficit of \$100.2 million at September 30, 2004. Based on the Company's 2004 and 2005 operating plans, management believes its existing sources of liquidity will be sufficient to meet its cash needs. If necessary, the Company's management believes they can manage costs and expenses at reduced levels to conserve working capital. The need for any such cost and expense reductions during 2004 and 2005 would likely delay implementation of the Company's business plan. Additionally, management may pursue additional financing alternatives. Ultimately, the Company must achieve sufficient revenue levels to support its cost structure.

Revenue Recognition.

Revenue on the sales of products is recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product. Our sales terms do not provide for the right of return unless the product is damaged or defective. Revenues from certain services associated with our analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. The Company also enters into various service contracts that cover installed WAVE Systems. These contracts cover specific time periods and revenue associated with these contracts is deferred and recognized over the service period.

During the first quarter of 2004, the Company recognized approximately \$196,000 of product sales under bill-and-hold arrangements. Under these arrangements, the customer had accepted title and risk of ownership to the product, but had requested that the Company store the product on behalf of the customer, in a rented freezer, until the second quarter of 2004.

During the second quarter of 2004, the Company recognized approximately \$450,000 of product sales under the bill-and-hold arrangement. Under these arrangements, the customer had accepted title and risk of ownership to the product, but had requested that the Company store the

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

product on behalf of the customer, in a rented freezer, until the third quarter of 2004. As of September 30, 2004, all products under these arrangements had been shipped to the respective customers.

Stock Based Compensation.

The Company accounts for its employee stock option grants under the provisions of Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees*, which utilizes the intrinsic value method. Accordingly, compensation cost for stock options is measured as the excess, if any, of the fair market value of the Company's common stock at the date of grant over the stock option exercise price. Stock option grants to nonemployees are accounted for using the fair value method of accounting in accordance with Statement of Financial Accounting Standards (SFAS) No. 123, *Accounting for Stock-Based Compensation*, using the Black-Scholes model.

Table of Contents**Transgenomic, Inc. and Subsidiaries****Notes to the Condensed Consolidated Financial Statements (Unaudited)****(In thousands except share and per share data)**

The following table illustrates the effect on net loss and loss per share if the Company had applied the fair value recognition provisions of SFAS No. 123, *Accounting for Stock-Based Compensation*, to stock based employee compensation.

	Three Months Ended		Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2004	2003	2004	2003
Net Loss:				
As reported	\$ (8,442)	\$ (6,097)	\$ (27,434)	\$ (14,364)
Pro forma	\$ (8,722)	\$ (6,498)	\$ (28,198)	\$ (15,685)
Basic and Diluted Loss Per Share:				
As reported	\$ (0.29)	\$ (0.25)	\$ (0.95)	\$ (0.61)
Pro forma	\$ (0.30)	\$ (0.27)	\$ (0.97)	\$ (0.66)

B. INVESTMENTS

As of September 30, 2004 and December 31, 2003, the Company had no available-for-sale securities.

In January and March 2004, the Company entered into addendums to an existing supply agreement with Geron Corporation. The addendums allowed Geron to pay for products being manufactured by the Company under the addendum with Geron common stock. As a result in January 2004, Geron issued 85,885 shares of common stock, valued at \$959,000, to the Company as a prepayment for products. On February 12, 2004 the Company sold these shares for \$932,000 resulting in a loss of \$27,000, which is reflected in the current earnings.

In March 2004, Geron issued 33,662 shares of common stock, valued at \$289,000, to the Company as a prepayment for products. In April 2004, Geron issued 140,872 shares of common stock, valued at \$1,288,000, to the Company as prepayment and payment for products. On July 1, 2004 the company sold these shares for \$1,361,328 resulting in a loss of \$215,672, which is reflected in the current earnings.

In July, 2004, Geron issued 75,247 shares of common stock, valued at \$601,371, to the Company as payment and prepayment for products. On July 28, 2004 and July 29, 2004, the Company sold these shares for \$474,212 resulting in a loss of \$127,159, which is reflected in the current earnings.

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

Included in accounts receivables at September 30, 2004 are amounts due from Geron totaling \$1.3 million. In October 2004 these Geron receivables were exchanged for 208,131 shares of Geron common stock. During November 2004, the Company sold these shares for \$1.5 million resulting in a gain of \$173,000 that will be recognized during the three months ending December 31, 2004.

All shares acquired from Geron during 2004 are being accounted for as available for sale securities.

In September 2003, the Company entered into an addendum to an existing supply agreement with Geron. The addendum allows Geron to pay for products being manufactured under the addendum with Geron as common stock. As a result, Geron issued 31,080 share of common stock to the Company as a prepayment for products. These shares are accounted for as available for sale securities.

In June 2003, the Company entered into a license agreement with Geron. As part of the agreement, the Company was required to purchase 310,000 share of Geron common stock for \$5.05 per share on June 3, 2002. On June 4, 2003, the Company sold the Geron shares. The purchase and sale of these shares was accounted for as a purchase and sale of trading securities. The purchase price was \$1,565,500 and the sale proceeds were \$1,519,000 resulting in a trading loss of \$46,500. This loss is reflected in current earnings.

Table of Contents**Transgenomic, Inc. and Subsidiaries****Notes to the Condensed Consolidated Financial Statements (Unaudited)****(In thousands except share and per share data)****C. INVENTORIES**

At September 30, 2004, and December 31, 2003, inventories consisted of the following:

	September 30,	December 31,
	2004	2003
	<u> </u>	<u> </u>
Finished goods	\$ 4,670	\$ 5,319
Raw materials and work in progress	4,956	5,074
Demonstration inventory	234	191
	<u> </u>	<u> </u>
Subtotal	9,860	10,584
Less inventories classified as a long term asset	2,667	
	<u> </u>	<u> </u>
	<u>\$ 7,193</u>	<u>\$ 10,584</u>

As of September 30, 2004, the Company had approximately \$5.0 million of chemical building block inventory. This inventory primarily includes phosphoramidites and the raw materials to produce phosphoramidites. Based on an analysis of these chemical building blocks as of September 30, 2004 and sales forecast for phosphoramidites, the Company classified \$2.7 million of this inventory as a long-term asset under Intangibles and Other Assets. The remaining chemical building block inventory of \$2.3 million is expected to be sold within twelve months and, accordingly, continues to be classified as current assets.

The Company periodically evaluates its inventory of chemical building blocks to determine whether they continue to meet quality and other specifications and over what time period such products are expected to be sold. Product that does not meet quality and other specifications can generally be re-worked to enhance purity. Cost to purify such product and related yield losses will be expensed as incurred.

D. INTANGIBLES AND OTHER ASSETS

At September 30, 2004, and December 31, 2003, finite lived intangible assets and other assets consisted of the following:

September 30, 2004

December 31, 2003

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

	Accumulated			Accumulated		
	Cost	Amortization	Net Book Value	Cost	Amortization	Net Book Value
Capitalized software	\$ 2,132	\$ 1,291	\$ 841	\$ 2,132	\$ 758	\$ 1,374
Intellectual property	765	227	538	765	165	600
Patents	1,074	188	886	1,035	170	865
Deferred financing costs	576	114	462	409		409
Long term inventory	2,667		2,667			
Other	605	188	417	656	183	473
Total	\$ 7,819	\$ 2,008	\$ 5,811	\$ 4,997	\$ 1,276	\$ 3,721

Amortization expense for intangible assets was \$242,121 and \$205,000 during the three months ended September 30, 2004, and 2003, respectively. The Company expects amortization expense for intangible assets to be approximately \$345,000 for the remainder of 2004, \$1,022,000 in fiscal 2005, \$367,000 in fiscal 2006, \$377,000 in fiscal 2007, \$77,000 in fiscal 2008, \$104,000 in fiscal 2009 and \$104,000 in fiscal 2010.

E. GOODWILL

At September 30, 2004, and December 31, 2003, goodwill by operating segment consisted of the following:

	BioSystems operating segment	Nucleic Acids operating segment	Total
Net balance December 31, 2003	\$ 638	\$ 9,865	\$ 10,503
Impairment charges		(9,865)	(9,865)
Net balance September 30, 2004	\$ 638	\$	\$ 638

Table of Contents**Transgenomic, Inc. and Subsidiaries****Notes to the Condensed Consolidated Financial Statements (Unaudited)****(In thousands except share and per share data)**

During the three months ended March 31, 2004, the Company's Board of Directors directed management to explore strategic alternatives for the Nucleic Acids operating segment. The ongoing process has included significant due diligence by management, its advisors and prospective independent buyers and other interested parties.

Based upon information obtained through this process during the three months ended June 30, 2004, management determined that it was more likely than not that the assets of the Nucleic Acids business were impaired. Accordingly, the Company engaged an external valuation firm to assist with the completion of a mid-year impairment test. As a result, the Company recorded a non-cash charge of \$11,964,387 related to its Nucleic Acids segment during the three months ended June 30, 2004. The charge consisted of \$9,864,387 related to the impairment of goodwill and \$2,100,000 related to the impairment of property and equipment.

F. STOCKHOLDERS' EQUITY AND STOCK OPTIONS

Other Comprehensive Income. Results of operations for the Company's foreign subsidiary are translated using the average exchange rates during the period. Assets and liabilities are translated at the exchange rate in effect on the balance sheet dates. These translation adjustments, along with unrealized gains and losses on available-for-sale securities, are the Company's only components of other comprehensive income.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2004	2003	2004	2003
Net loss	\$ (8,442)	\$ (6,097)	\$ (27,434)	\$ (14,364)
Unrealized gain on available for sale securities		148		148
Currency translation adjustments	(126)	116	29	283
Total comprehensive loss	\$ (8,568)	\$ (5,833)	\$ (27,405)	\$ (13,933)

Stock Options. During the nine months ended September 30, 2004, the Company granted 360,000 options at an exercise price of between \$1.32 to \$2.57 per share. The following table summarizes activity under the 1997 Stock Option Plan during the nine months ended September 30, 2004.

Number of Options	Weighted Average Exercise Price
-------------------------	---------------------------------------

Balance at December 31, 2003	5,692,916	\$ 5.37
Granted	360,000	\$ 1.74
Exercised		
Forfeited	(317,133)	\$ 5.05
Balance at September 30, 2004	5,735,783	\$ 5.15
Exercisable at September 30, 2004	4,362,839	\$ 5.80

The weighted average fair value of options granted during the first nine months of fiscal 2004 was \$1.34 per share. The fair value of each stock option granted is estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for options granted in the first nine months of fiscal 2004: no common stock dividends; risk-free interest rates of 4.14% to 4.79%; 85% volatility; and an expected option life of 3 years. At September 30, 2004, the weighted average remaining contractual life of options outstanding was 5.6 years.

G. COMMITMENTS AND CONTINGENCIES

The Company has been named as a defendant in a lawsuit filed in Spain by a prospective distributor who claims that the Company breached a promise to grant the plaintiff a distributorship for certain of the Company's products in a specific geographic area in Europe. The plaintiff is seeking monetary relief of approximately \$500,000. The Company believes the lawsuit is without merit and intends to vigorously defend this matter.

The Company is subject to a number of other claims of various amounts, which arise out of the normal course of its business. In the opinion of management, the disposition of all claims currently pending will not have a material adverse effect on the Company's financial position, results of operations or cash flows.

Table of Contents

Transgenomic, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In thousands except share and per share data)

H. INCOME TAXES

The Company's tax expense (benefit) relates to its operations in certain foreign countries and certain states. The tax benefit recorded during the nine months ended September 30, 2004 relates to refunds received in the United Kingdom. Due to the Company's cumulative losses, expected losses in future years and inability to utilize any additional losses as carrybacks, the Company has not provided for an income tax benefit during the nine months ended September 30, 2004, based on management's determination that it was more likely than not that such benefits would not be realized. The Company will continue to assess the recoverability of deferred tax assets and the related valuation allowance. To the extent the Company begins to generate taxable income in future periods and it determines that such valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized at such time. As of September 30, 2004, and December 31, 2003, the Company's deferred tax assets were offset by a valuation allowance of approximately \$41.4 million and \$30.6 million, respectively.

I. OPERATING SEGMENT AND GEOGRAPHIC INFORMATION

The Company's operations are managed based upon the nature of the products and services provided. Accordingly, the Company has determined that it operates in two segments, BioSystems and Nucleic Acids. Operations for these segments are evaluated based upon specific identification of revenues and expenses associated with the business activities resulting in segment operating income (loss). Expenses that cannot be directly identified to an operating activity or are considered corporate overhead are not allocated to the segments in arriving at operating income (loss) for the segment. Generally, decisions regarding asset allocation, financing, or other items impacting the Company's balance sheet are made at the corporate level and, accordingly, balance sheet information is not typically reviewed by operating segment.

The BioSystems operating segment generates revenue from the sale of automated instrument systems and associated consumable products and services. This segment's products are based upon separations chemistries and enzymology. Specifically, this segment's main products are the WAVE System, related bioconsumables and research services.

The Nucleic Acids operating segment generates revenue from the sale of products and services based upon nucleic acid chemistries, separations chemistries and enzymology. Specifically, this segment's main products are nucleic acid building blocks or phosphoramidites, oligonucleotides, fluorescent markers, dyes and associated reagents and novel chemistry and process development services.

The following is information for net sales and loss from operating income by segment.

Three Months Ended September 30,	Nine Months Ended September 30,
---	--

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

	<u>2004</u>	<u>2003</u>	<u>2004</u>	<u>2003</u>
Sales				
BioSystems	\$ 5,501	\$ 6,083	\$ 18,450	\$ 19,680
Nucleic Acids	2,693	1,454	7,384	5,841
Total	\$ 8,194	\$ 7,537	\$ 25,834	\$ 25,521
Loss from Operations				
BioSystems	\$ (634)	\$ (768)	\$ (1,309)	\$ (2,056)
Nucleic Acids, including impairment charge of \$11,964 in 2004 (Note E)	(2,512)	(3,448)	(17,073)	(6,205)
Corporate	(1,613)	(1,751)	(4,442)	(5,793)
Total	\$ (4,759)	\$ (5,967)	\$ (22,824)	\$ (14,054)

J. LINE OF CREDIT AND LONG-TERM DEBT

In December 2003, the Company entered into a \$7.5 million line of credit (the **Credit Line**) with Laurus Master Fund, Ltd. (**Laurus**). The term of the **Credit Line** is three years carrying an interest rate of 2.0% over the prime rate or a minimum of 6.0%. Funds available under the **Credit Line** are determined by a borrowing base equal

Table of Contents

Transgenomic, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In thousands except share and per share data)

to 90% of eligible accounts receivable balances plus up to \$1.0 million related to inventory balances. The Credit Line is secured by most of the Company's assets. Prior to amendments to the Credit Line discussed below, payment of interest and principal could, under certain circumstances, be made with shares of the Company's common stock at a fixed conversion price of \$2.20 per share. Conversion of this debt to common stock may be made at the election of Laurus or the Company. The Company could elect to convert only if its shares trade at a price exceeding \$2.42 per share for ten consecutive trading days, and such conversion is further subject to trading volume limitations and a limitation on the total beneficial ownership by Laurus of the Company's common stock. Upon entering into the Credit Line, the Company issued warrants to Laurus to acquire 550,000 shares of the Company's common stock at an exercise price exceeding the average trading price of the Company's common stock over the ten trading days prior to the date of the warrant. As of September 30, 2004, the Company had approximately \$7.1 million outstanding on the Credit Line.

In February 2004, the Company entered into a separate \$2.75 million convertible note with Laurus (the Term Note). The Term Note carries an interest rate of 2.0% over the prime rate or a minimum of 6.0% and has a term of 3 years. Prior to amendments to the Term Note discussed below, the principal and interest on the Term Note could be converted into common stock of the Company at a fixed conversion price of \$2.61 per share. Upon entering the Term Note, the Company issued warrants to Laurus to acquire 125,000 shares of its common stock. Borrowings under the Term Note were primarily used to retire the mortgage debt on the Company's Glasgow facility. Remaining borrowings of approximately \$750,000 were used to complete the build-out of the Glasgow facility, complete the consolidation the Company's Glasgow operations into the new facility and provide funds for operations.

Certain features of the Credit Line and Term Note (collectively, the Laurus Loans) require the Company to separately account for the value of certain amounts related to the warrants issued and the conversion feature of the Laurus Loans. Specifically, Emerging Issues Task Force (EITF) No. 00-27, *Application of Issue No. 98-5 to Certain Convertible Instruments*, requires the Company to separately value the warrants issued and the beneficial conversion premium related to the Laurus Loans. Any borrowings under the Credit Line may result in additional beneficial conversion premiums. The values of the warrants and the beneficial conversion premium have been recorded on the balance sheet as a debt discount and an increase to additional paid in capital. The debt discount recorded for these items will be amortized as expense to the income statement over the terms of the Laurus Loans or as the warrants are exercised or the debt is converted into common stock thereby increasing the effective interest rate on the Laurus Loans. In January and February 2004, Laurus exercised its conversion rights on the Credit Line and converted \$2.0 million of amounts outstanding on the Credit Line into approximately 910,000 shares of common stock of the Company. In connection with this conversion, the Company accelerated the amortization of approximately \$539,000 of the beneficial conversion premium.

In February 2004, Laurus waived the borrowing base limitation on the Credit Line, thereby making the full \$7.5 million facility available to the Company regardless of the available collateral. On August 31, 2004, Laurus agreed to extend the borrowing base waiver on the Credit Line through March 19, 2005. In addition, Laurus deferred certain payments due under the Term Note and reduced the interest rate on both of the Laurus Loans to 0% for any day the closing sale price of the Company's common stock is at or above \$1.75 per share. In return, the Company lowered the conversion price on each of the Laurus Loans to \$1.00 per share and issued a warrant to Laurus covering an additional 400,000 common shares at an exercise price of \$1.25 per share. The closing price of the Company's common stock on August 31, 2004 was \$1.20 per share.

The August 31, 2004 Laurus modifications were treated as extinguishments for financial reporting purposes since the change in present value of expected cash flows between the original and modified agreements is greater than 10%. As such, the Company recorded a loss on extinguishment of debt of \$2.9 million at August 31, 2004 reflecting the difference between (i) the recorded amount of debt, net of related

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

discounts, of \$7.4 million and (ii) the fair value of the new debt instrument of \$10.3 million plus the fair value of the new warrants of \$120,000. The difference between the fair value of the new debt of \$10.3 million and the face value of the debt of \$8.6 million represents a premium, which will be reflected as a reduction of interest expense over the life of the new debt.

Prospectively, draws on the Credit Line may result in beneficial conversion charges to the extent the price of the Company's common stock exceeds the conversion price on the day of the draw. Such beneficial charges will be amortized as expense to the income statement during the period the draw remains outstanding or up to the point the debt is converted into common stock thereby increasing the effective interest rate on the Credit Line.

Table of Contents**Transgenomic, Inc. and Subsidiaries****Notes to the Condensed Consolidated Financial Statements (Unaudited)****(In thousands except share and per share data)**

The following table details the components of the Company's Credit Line, Term Loan and other debt as of September 30, 2004 and December 31, 2003.

	September 30,	December 31,
	2004	2003
	<u> </u>	<u> </u>
Line of Credit	\$ 7,089	\$ 2,992
Debt Premium	1,124	
Less:		
Debt discount - warrants	97	370
Debt discount - beneficial conversion premium	210	480
	<u> </u>	<u> </u>
	\$ 7,906	\$ 2,142
	<u> </u>	<u> </u>
Long-term debt		
Convertible debt	2,750	
Mortgage debt		1,693
Debt Premium	531	
Less:		
Current portion	975	(1,693)
	<u> </u>	<u> </u>
	\$ 2,306	\$
	<u> </u>	<u> </u>

K. CORPORATE RESTRUCTURING

The Company has historically experienced net losses and negative cash flows from operations. As a result, during the fourth quarter of fiscal 2002, management formulated a restructuring plan designed to reduce expenses thereby better aligning the Company's expense structure with current business prospects. The plan included employee terminations, office closures, and termination of collaborations and write-offs of abandoned intellectual property. A significant portion of the plan was executed in the fourth quarter of 2002 resulting in the recording of \$3.3 million in restructuring charges. The Company had accrued expenses and other liabilities associated with the restructuring activities of approximately \$3,365 and \$227,000 at September 30, 2004, and December 31, 2003, respectively. The accrued expenses at September 30, 2004, were related to lease payments associated with office closures.

L. SUBSEQUENT EVENTS

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

Sale of Specialty Oligonucleotides Facility. On November 11, 2004, the Company sold the assets associated with its specialty oligonucleotides manufacturing facility in Boulder, Colorado to a subsidiary of Eyetech Pharmaceuticals, Inc. (Eyetech). The sale price was \$3.0 million in cash plus the assumption of the lease on the Boulder facility and certain equipment leases with a gross value of \$2.3 million. Substantially all of the 27 employees at the Boulder facility became Eyetech employees. Net proceeds from the sale (after transaction expenses and fees paid to the Company's investment advisors) equaled approximately \$2.7 million, subject to a holdback of \$300,000 that will be held in escrow for 90 days for liabilities for representations and warranties and to pay the costs of moving certain acquired assets to the Boulder facility. The net proceeds will be used primarily for general working capital purposes and to repay a portion of the Credit Line. The sale will be recognized during the quarter ending December 31, 2004 and is not expected to a significant effect on earnings during that quarter.

Restructuring Plan. On November 13, 2004, the Board of Directors approved a restructuring plan designed to refocus the Company on its BioSystems business segment and to align the Company's cost structure with anticipated revenues. The plan (which is incremental to the sale of the Boulder facility previously summarized) includes a workforce reduction of approximately 60 positions and the closure of two domestic research and development facilities associated with the Company's nucleic acids operation segment and two European field offices. The majority of workforce reductions will be completed by the end of November 2004. The plan is expected to yield annualized savings of \$6.0 to \$8.0 million once the cost reductions are fully implemented in the first quarter

2005. In conjunction with the plan, the Company expects to incur a charge of between \$1.5 million to \$1.8 million during the quarter ending December 31, 2004, related primarily to severance, benefits and facility closures.

Table of Contents

Transgenomic, Inc. and Subsidiaries

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(In thousands except share and per share data)

M. RESTATEMENT OF CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Subsequent to the issuance of the Company's financial statements for the year ended December 31, 2004, the Company's management determined that it had incorrectly included the amortization of software development costs within net cash flows from investing activities rather than within net cash flows from operating activities.

As a result, the Company's condensed consolidated statements of cash flows for the nine months ended September 30, 2004 and 2003 have been restated from the amounts previously reported to correct these errors. This restatement had no impact on the Company's condensed consolidated balance sheets or condensed consolidated statements of operations. The impact of this restatement on the condensed consolidated statements of cash flows is as follows: (dollars in thousands):

	Nine Months Ended September 30, 2004		Nine Months Ended September 30, 2003	
	As Previously Reported	As Restated	As Previously Reported	As Restated
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Depreciation and amortization	\$ 3,145	\$ 3,607	\$ 2,850	\$ 3,312
Net cash flows from operating activities	(9,170)	(8,708)	(9,880)	(9,418)
Change in other assets	488	26	310	(152)
Net cash flows from investing activities	2,006	1,544	(1,724)	(2,186)

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following analysis gives effect to the restatement of our condensed consolidated statements of cash flows for the nine months ended September 30, 2004 and 2003, as discussed in Note M to the accompanying unaudited condensed consolidated financial statements.

Overview

We provide innovative products and services for the synthesis, purification and analysis of nucleic acids. We develop, assemble, manufacture and market our products and services to the life sciences industry to be used in research focused on molecular genetics of humans and other organisms. Such research could lead to development of new diagnostics and therapeutics. Our products can be used to analyze DNA or RNA at the molecular level, amplify, separate, and isolate nucleic acid fragments of particular interest and synthesize conventional or chemically-modified nucleic acid molecules. These capabilities are central to research seeking to discover and understand variations in the genetic code, the relationship of these variations to disease and, ultimately, to develop diagnostics and therapeutics based on this understanding. Our business plan is to participate in the value chain associated with these activities by providing key technology, tools, consumables, biochemical reagents and services to those entities engaged in basic biomedical research and the development of diagnostics and therapeutic agents.

The Company's operations are managed based upon the nature of the products and services provided. Accordingly, the Company has determined that it operates in two segments, BioSystems and Nucleic Acids. Operations for these segments are evaluated based upon specific identification of revenues and expenses associated with the business activities resulting in a segment operating income. Expenses that cannot be directly identified to an operating activity or are considered corporate overhead are not allocated to the segments in arriving at operating income for the segment.

The BioSystems operating segment generates revenue from the sale of automated instrument systems and associated consumable products and services. This segment's products are based upon separations chemistries and enzymology. Specifically, this segment's main products are the WAVE System, related bioconsumables and research services. Since the WAVE System product introduction in 1997, we have sold over 1,000 instruments to customers in over 30 countries.

The Nucleic Acids operating segment has been engaged in the manufacture of nucleic acid building blocks or phosphoramidites, oligonucleotides, fluorescent markers, dyes and associated reagents and novel chemistry and process development services. This operating segment has historically operated at a loss and the Company has been exploring strategic alternatives regarding this operating segment during 2004. On November 11, 2004, we sold the assets associated with our specialty oligonucleotide manufacturing facility in Boulder, Colorado to a subsidiary of Eyetech Pharmaceuticals, Inc. As a result, we no longer manufacture and sell oligonucleotides.

Executive Summary and Operating Strategy

We have incurred significant losses resulting principally from costs incurred in research and development and selling, general and administrative costs associated with our operations. At September 30, 2004, we had an accumulated deficit of \$100.2 million. Our liquidity and working capital positions deteriorated during the quarter predominately due to operating losses. These operating losses were funded primarily by borrowings under our credit facility and reductions in accounts receivables.

While we expect to continue to incur substantial research and development and selling, general and administrative costs, we have implemented an operating strategy which is designed to refocus on the BioSystems segment of our business and to align our cost structure with projected revenues. We have initiated the following steps to accomplish this objective.

Strategic Alternatives For Our Nucleic Acids Operating Segment. Our Nucleic Acids operating segment has historically operated at a loss and produced negative cash flow. While we believe the long-term prospects for this business segment are favorable, the projected levels of near-term revenues from this segment are not expected to generate either positive cash flows or profits from operations. After considering, among other factors, the historical financial results of this division and the near-term outlook for the nucleic acids industry, our

Table of Contents

Board of Directors directed management to explore strategic alternatives for this operating segment, including the possible sale of one or both of the facilities in Glasgow, Scotland and Boulder, Colorado. On November 11, 2004, the Company sold the assets associated with its specialty oligonucleotide manufacturing facility in Boulder, Colorado to a subsidiary of Eyetech Pharmaceuticals, Inc. (Eyetech). The sale price was \$3.0 million in cash plus the assumption of the lease on the Boulder facility and certain equipment leases with a gross value of \$2.3 million. Substantially all of the 27 employees at the Boulder facility became Eyetech employees. Net proceeds from the sale (after transaction expenses and fees paid to our investment advisors) equaled approximately \$2.7 million, subject to a holdback of \$300,000 that will be held in escrow for 90 days for liabilities for representations and warranties and to pay the costs of moving certain acquired assets to the Boulder facility. The net proceeds will be used primarily for general working capital purposes and to repay portion of our credit line. We have also taken steps to downsize our remaining nucleic acids facility in Glasgow, Scotland as part of the restructuring plan described below.

Restructuring Plan. On November 13, 2004, the Board of Directors approved a restructuring plan designed to refocus the Company on its BioSystems business segment and to align the Company's cost structure with anticipated revenues. The plan (which is incremental to the sale of the Boulder facility previously summarized) includes a workforce reduction of approximately 60 positions and the closure of two domestic research and development facilities associated with our nucleic acids operating segment and two European field offices. The majority of workforce reductions will be completed by the end of November 2004. The plan is expected to yield annualized savings of \$6.0 to \$8.0 million once the cost reductions are fully implemented in the first quarter 2005. In conjunction with the plan, the Company expects to incur a charge of between \$1.5 million to \$1.8 million during the quarter ending December 31, 2004 related primarily to severance, benefits and facility closures. Additionally, we have adopted processes to improve the collection of accounts receivables, especially with respect to sales in European markets which historically have longer payment cycles. Finally, we have taken steps to more appropriately align the timing of our inventory acquisitions with anticipated sales.

Together, the sale of our oligonucleotide manufacturing facility and the November 13, 2004 restructuring plan, is expected to result in \$10.0 to \$12.0 million in annual cost savings.

Revisions to Credit Facilities. We have entered into a \$7.5 million line of credit (the Credit Line) and a separate \$2.75 million convertible note with Laurus (the Term Note) with Laurus Master Fund, Ltd. (Laurus) (collectively, the Laurus Loans). In February 2004, Laurus waived the borrowing base limitation on the Credit Line, thereby making the full \$7.5 million facility available to the Company regardless of the available collateral. On August 31, 2004, Laurus agreed to extend the borrowing base waiver on the Credit Line through March 19, 2005. In addition, Laurus has deferred certain payments due under the Term Note and reduced the interest rate on both of the Laurus Loans to 0% for any day the closing sale price of the Company's common stock is at or above \$1.75 per share). In return, we lowered the conversion price on each of the Laurus Loans to \$1.00 per share and issued a warrant to Laurus covering an additional 400,000 common shares at an exercise price of \$1.25 per share. The closing price of the Company's common stock on August 31, 2004 was \$1.20 per share.

The revisions to the Laurus Loans agreements, along with the anticipated liquidity benefits resulting from the sale of the Boulder facility and implementation of the restructuring plan are expected to significantly improve our liquidity position. However, there can be no assurance that these initiatives alone will be sufficient to allow the Company to operate without additional capital.

Table of Contents**Results of Operations Three Months Ended September 30, 2004 and 2003**

<u>Amounts in thousands</u>	<u>2004</u>	<u>2003</u>	<u>Change</u>	<u>%</u> <u>Change</u>
Net Sales				
Bioinstruments and Discovery Services	\$ 3,444	\$ 4,295	\$ (851)	(20)%
Bioconsumables	2,057	1,788	269	15%
Total BioSystems Business Unit	5,501	6,083	(582)	(10)%
Chemical Building Blocks	2,280	1,038	1,242	120%
Specialty Oligonucleotides and Services	413	416	(3)	(1)%
Total Synthetic Nucleic Acids Business Unit	2,693	1,454	1,239	85%
Total Net Sales	8,194	7,537	657	9%
Cost of Goods Sold				
Bioinstruments and Services	1,584	1,921	(337)	(18)%
Bioconsumables	1,077	810	267	33%
Total BioSystems Business Unit	2,661	2,731	(70)	(3)%
Chemical Building Blocks	2,659	2,355	304	13%
Specialty Oligonucleotides and Services	1,537	1,676	(139)	(8)%
Total Synthetic Nucleic Acids Business Unit	4,196	4,031	(165)	(4)%
Total Cost of Goods Sold	6,857	6,762	95	1%
Selling, General and Administrative Expenses	4,353	4,331	22	1%
Research and Development Expenses	1,743	2,411	(668)	(28)%
Other Income (Expense)	(3,682)	(105)	(3,577)	%
Income Tax Expense (Benefit)	1	25	(24)	96%

Net Sales. Net sales during the third quarter of 2004 increased 9% from the third quarter of 2003, as a result of 10% reduction in sales in our BioSystems operating segment offset by 85% increase in sales in our Nucleic Acids operating segment.

The decrease in BioSystems sales resulted from a 27% decline in revenues from the sales of bioinstruments. This reduction was partially offset by a 99% increase from discovery services and a 15% increase in bioconsumables. Net sales of software upgrades, service contracts and consumable products continued to increase due to a larger installed base of WAVE Systems. Increased discovery services revenue is attributable to a focus on providing genetic variation discovery and analysis services to our pharmaceutical base of customers. In December 2003, we announced a discovery services agreement with Novartis Pharmaceuticals Corp. supporting the clinical development of oncology therapeutics. We believe that genetic variation discovery and analysis services provide us a significant opportunity to expand revenues in the future.

Sales in our Nucleic Acid operating segment increased by 85% in the third quarter of 2004 compared to the third quarter of 2003 as a result of a substantial increase in sales of our chemical building block products, primarily to Geron Corporation. Sales of oligonucleotide products remained flat during the period. These products are used by our biopharmaceutical and pharmaceutical customers as raw materials in DNA based drug candidates and demand is affected by the timing of completion and/or failure clinical trials for these drug candidates. As a result of the sale of our Boulder, Colorado facility in November 2004, we no longer manufacture or sell oligonucleotides.

Cost of Goods Sold. Cost of goods sold remained relatively flat year to year despite the increase in our revenues. Fixed costs associated with excess manufacturing capacity in our Nucleic Acids business unit and a lower number of high margin WAVE Systems sold kept our cost of goods sold comparable to the third quarter of 2003. The BioSystems business unit cost of goods sold as a percentage of sales increased year over year but remained within historical ranges at 45% to 50%. We expect that our BioSystems margins will fluctuate within historical ranges based upon the sales mix of systems, consumables and services. Currently our Nucleic Acid products are sold at lower margins compared to our BioSystems products. The margins in our Nucleic Acids business unit have been negatively impacted by higher manufacturing costs and excess capacity due largely to our plant expansion efforts in Glasgow, Scotland and Boulder, Colorado.

As a result of the sale of our Boulder, Colorado facility and the restructuring plan implemented in November 2004, we anticipate that our cost of goods sold for our Nucleic Acid products will be significantly improved. However, until demand for our Nucleic Acid products increase we will continue to have excess manufacturing capacity and lower than expected margins.

Selling, General and Administrative Expenses. Selling, general and administrative expenses increased slightly as a result of increased costs in our Glasgow, Scotland facility offset by reductions in personnel and personnel related expenses and travel costs attributed to the decrease, offset by foreign currency increases.

Research and Development Expenses. Research and development expenses decreased as a result of our focus on expense control. Reductions in personnel, personnel related expenses and outside services all contributed to the decrease. We expense our research and development costs in the year in which they are incurred.

Table of Contents

Other Income (Expense). Other income (expense) includes of interest and investment income, interest expense and loss on debt extinguishment.

Interest and investment income (loss) totaled \$(345,000) in the third quarter of 2004 compared to \$2,000 during the same period of 2003. The decrease related primarily to losses realized on the sale of Geron stock. As described in Note B to the condensed consolidated financial statements, Geron has paid us for products with Geron common stock that we have accounted for as available for sale securities.

Interest expense was \$378,000 in the third quarter of 2004 compared to \$98,000 for the same period of 2003. The increase related to a significantly higher debt burden and a slightly higher cost of funds.

Loss on debt extinguishment totaled \$2.9 million in the third quarter of 2004. As described in Note J to the condensed consolidated financial statements, certain August 31, 2004 modifications to our Laurus facilities were treated as extinguishments for financial reporting purposes since the change in present value of expected cash flows between the original and modified agreements is greater than 10%. As such, the Company recorded a loss on extinguishment of debt of \$2.9 million at August 31, 2003 reflecting the difference between (i) the recorded amount of debt, net of related discounts, of \$7.4 million and (ii) the fair value of the new debt instrument of \$10.3 million plus the fair value of the new warrants of \$120,000. The difference between the fair value of the new debt of \$10.3 million and the face value of the debt of \$8.6 million represents a premium, which will be reflected as a reduction of interest expense over the life of the new debt.

Income Tax Expense. The Company's tax expense (benefit) relates to its operations in certain foreign countries and certain states. The tax benefit recorded in the third quarter of 2004 relates to refunds received in the United Kingdom. No further tax benefits are being recorded due to the uncertainty as to whether we will be able to utilize any additional losses as carrybacks. We will continue to assess the recoverability of deferred tax assets and the related valuation allowance. We expect to continue to incur losses and expect to continue to provide valuation allowances against deferred tax assets. To the extent we begin to generate taxable income in future years and it is determined that such valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized.

Results of Operations Nine Months Ended September 30, 2004 and 2003

<u>Amounts in thousands</u>	<u>2004</u>	<u>2003</u>	<u>Change</u>	<u>%</u> <u>Change</u>
Net Sales				
Bioinstruments and Discovery Services	\$ 12,164	\$ 14,529	\$ (2,365)	(16)%
Bioconsumables	6,286	5,180	1,106	21%
Total BioSystems Business Unit	18,450	19,709	(1,259)	(6)%
Chemical Building Blocks	5,588	5,022	566	11%
Specialty Oligonucleotides and Services	1,796	790	1,006	127%
Total Synthetic Nucleic Acids Business Unit	7,384	5,812	1,572	27%
Total Net Sales	25,834	25,521	313	1%
Cost of Goods Sold				
Bioinstruments and Services	5,442	6,014	(572)	(10)%
Bioconsumables	2,981	2,565	416	16%

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

Total BioSystems Business Unit	8,423	8,579	(156)	(2)%
Chemical Building Blocks	5,452	5,749	(297)	(12)%
Specialty Oligonucleotides and Services	4,609	4,171	438	11%
Total Synthetic Nucleic Acids Business Unit	10,061	9,920	141	1%
Total Cost of Goods Sold	18,484	18,500	(15)	%
Selling, General and Administrative Expenses	12,866	13,239	(373)	(3)%
Research and Development Expenses	5,344	7,098	(1,755)	(25)%
Impairment Charges	11,964		11,964	%
Restructuring and Restructuring Related Charges		738	(738)	(100)%
Other Income (Expense)	(4,704)	(261)	(4,443)	1,702%
Income Tax Expense (Benefit)	(94)	49	(143)	(292)%

Table of Contents

Net Sales. Net sales during the nine months ended September 30, 2004 increased 1% from the same period of 2003, as a result of a 27% increase in sales in our Nucleic Acids operating segment offset by a 6% reduction in sales in our BioSystems operating segment.

Sales in our Nucleic Acid operating segment increased by 27% in the nine months ended September 30, 2004 compared to the same period of 2003 as a result of increases in sales of our chemical building block products, primarily to Geron Corporation and substantial increases in sales of oligonucleotides. These products are used by our biopharmaceutical and pharmaceutical customers as raw materials in DNA based drug candidates and demand is affected by the timing of completion and/or failure clinical trials for these drug candidates. As a result of the sale of our Boulder, Colorado facility in November 2004, we will no longer manufacture or sell oligonucleotides.

The decrease in BioSystems sales resulted from a 16% decrease in bioinstrument and discovery services sales offset by a 21% increase in bioconsumable sales. This resulted from a 24% decline in revenues from the sales of bioinstruments. This reduction was partially offset by a 309% increase from discovery services and a 21% increase in bioconsumables. Net sales of software upgrades, service contracts and consumable products continued to increase due to a larger installed base of WAVE Systems. Increased discovery services revenue is attributable to a focus on providing genetic variation discovery and analysis services to our pharmaceutical base of customers. In December 2003, we announced a discovery services agreement with Novartis Pharmaceuticals Corp. supporting the clinical development of oncology therapeutics. We believe that genetic variation discovery and analysis services provide us a significant opportunity to expand revenues in the future.

Cost of Goods Sold. Cost of goods sold remained relatively flat year to year despite the increases in our revenues. Fixed costs associated with excess manufacturing capacity in our Nucleic Acids business unit and a lower number of high margin WAVE Systems sold kept our cost of goods sold comparable to the prior period. The BioSystems business unit cost of goods sold as a percentage of sales increased year over year but remained within historical ranges at 45% to 50%. We expect that our BioSystems margins will fluctuate within historical ranges based upon the sales mix of systems, consumables and services. Currently our Nucleic Acid products are sold at lower margins compared to our BioSystems products. The margins in our Nucleic Acids business unit have been negatively impacted by higher manufacturing costs and excess capacity due largely to our plant expansion efforts in Glasgow, Scotland and Boulder, Colorado.

As a result of the sale of our Boulder, Colorado facility and the restructuring plan implemented in November 2004, we anticipate that our cost of goods sold for our Nucleic Acid products will be significantly improved. However, until demand for our Nucleic Acid products increase we will continue to have excess manufacturing capacity and lower margins.

Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased slightly as a result of our focus on expense control. Reductions in personnel and personnel related expenses and travel costs attributed to the decrease, offset by foreign currency increases.

Research and Development Expenses. Research and development expenses decreased as a result of our focus on expense control. Reductions in personnel, personnel related expenses and outside services all contributed to the decrease. We expense our research and development costs in the year in which they are incurred.

Impairment Charges. During the three months ended March 31, 2004, our Board of Directors directed us to explore strategic alternatives for the Nucleic Acids operating segment. The ongoing process has included significant due diligence by us, our advisors and prospective independent buyers and other interested parties.

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

Based upon information obtained through this process during the three months ended June 30, 2004, we determined that it was more likely than not that the assets of the Nucleic Acids business were impaired. Accordingly, we engaged an external valuation firm to assist with the completion of a mid-year impairment test. As a result, we recorded a non-cash charge of \$12.0 million related to its Nucleic Acids segment during the three months ended June 30, 2004. The charge consisted of \$9.9 million related to the impairment of goodwill and \$2.1 million related to the impairment of property and equipment.

Restructuring Charges. During the fourth quarter of 2002 management formulated and executed a significant portion of a restructuring plan. The plan was developed to reduce expenses thereby better aligning the Company's

Table of Contents

expense structure with current business prospects. The plan included employee terminations, office closures, termination of collaborations and write-offs of abandoned intellectual property. We continued to execute the plan during the first quarter of 2003 resulting in the additional charges recorded in 2003. These charges consisted of mainly employee severance costs and office closings. We have not incurred any significant restructuring charges in the nine months ended September 30, 2004.

Other Income (Expense). Other income (expense) includes of interest and investment income, interest expense and loss on debt extinguishment.

Interest and investment income (loss) totaled \$(371,000) in the nine months ended September 30, 2004 compared to \$48,000 during the same period of 2003. The decrease related primarily to losses realized on the sale of Geron stock. As described in Note B to the condensed consolidated financial statements, Geron has paid us for products with Geron common stock that we have accounted for as available for sale securities.

Interest expense was \$1.3 million in the nine months ended September 30, 2004 compared to \$191,000 for the same period of 2003. The increase related to a significantly higher debt burden and a slightly higher cost of funds.

Loss on debt extinguishment totaled \$2.9 million in the nine months ended September 30, 2004. As described in Note J to the condensed consolidated financial statements, certain August 31, 2004 modifications to our Laurus facilities were treated as extinguishments for financial reporting purposes since the change in present value of expected cash flows between the original and modified agreements is greater than 10%. As such, the Company recorded a loss on extinguishment of debt of \$2.9 million at August 31, 2004 reflecting the difference between (i) the recorded amount of debt, net of related discounts, of \$7.4 million and (ii) the fair value of the new debt instrument of \$10.3 million plus the fair value of the new warrants of \$120,000. The difference between the fair value of the new debt of \$10.3 million and the face value of the debt of \$8.6 million represents a premium, which will be reflected as a reduction of interest expense over the life of the new debt.

Income Tax Expense. The Company's tax expense (benefit) relates to its operations in certain foreign countries and certain states. The tax benefit recorded in the nine months ended September 30, 2004 relates to refunds received in the United Kingdom. No further tax benefits are being recorded due to the uncertainty as to whether we will be able to utilize any additional losses as carrybacks. We will continue to assess the recoverability of deferred tax assets and the related valuation allowance. We expect to continue to incur losses and expect to continue to provide valuation allowances against deferred tax assets. To the extent we begin to generate taxable income in future years and it is determined that such valuation allowance is no longer required, the tax benefit of the remaining deferred tax assets will be recognized.

Liquidity and Capital Resources

Overview

As of September 30, 2004, we had approximately \$1.1 million in cash and cash equivalents. At November 15, 2004, we had cash and cash equivalents of \$500,000 plus an additional \$2.8 available under our Credit Line. The increase in cash and cash equivalents from September 30, 2004, relates primarily to the sale of our Boulder, Colorado facility.

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

We have experienced recurring net losses and had an accumulated deficit of \$100.2 million at September 30, 2004. Based on our 2004 and 2005 operating plans, we believe existing sources of liquidity will be sufficient to meet cash needs. If necessary, we believe we can manage costs and expenses at reduced levels to conserve working capital. The need for any such cost and expense reductions during 2004 or 2005 would likely delay implementation of our business plan. Additionally, we may pursue additional financing alternatives. Ultimately, we must achieve sufficient revenue levels to support its cost structure.

Table of Contents

The following table summarizes our short-term liquidity and sources and uses of cash, as of September 30, 2004 and December 31, 2003 and for the three months ended September 30, 2004 and 2003:

<u>Amounts in Thousands</u>	<u>September 30,</u> <u>2004</u>	<u>December 31,</u> <u>2003</u>
Short-term liquidity:		
Current assets	\$ 20,324	\$ 24,378
Current liabilities	(18,182)	(12,248)
Net working capital	2,142	12,130
Cash and cash equivalents	1,125	1,241
Available borrowings on line of credit	400	1,673
	For the period ended September 30, 2004	For the period ended September 30, 2003
Net cash flows:		
Operating activities	\$ (8,708)	\$ (9,418)
Investing activities	1,544	(2,186)
Financing activities	7,185	3,158
Effect of foreign currency exchange rates on cash	(137)	(148)
Net change in cash and cash equivalents	\$ (116)	\$ (8,594)

In December 2003, we entered into a \$7.5 million line of credit (the "Credit Line") with Laurus Master Fund, Ltd. ("Laurus"). The term of the Credit Line is three years carrying an interest rate of 2.0% over the prime rate or a minimum of 6.0%. Funds available under the Credit Line are determined by a borrowing base equal to 90% of eligible accounts receivable balances plus up to \$1.0 million related to inventory balances. The Credit Line is secured by most of the Company's assets. Prior to amendments to the Credit Line discussed below, payment of interest and principal could, under certain circumstances, be made with shares of the Company's common stock at a fixed conversion price of \$2.20 per share. Conversion of this debt to common stock may be made at the election of Laurus or the Company. We could elect to convert only if its shares trade at a price exceeding \$2.42 per share for ten consecutive trading days, and such conversion is further subject to trading volume limitations and a limitation on the total beneficial ownership by Laurus of our common stock. Upon entering into the Credit Line, we issued warrants to Laurus to acquire 550,000 shares of our common stock at an exercise price exceeding the average trading price of our common stock over the ten trading days prior to the date of the warrant. As of September 30, 2004, we had approximately \$7.1 million outstanding on the Credit Line.

In February 2004, we entered into a separate \$2.75 million convertible note with Laurus (the "Term Note"). The Term Note carries an interest rate of 2.0% over the prime rate or a minimum of 6.0% and has a term of 3 years. Prior to amendments to the Term Note discussed below, the principal and interest on the Term Note could be converted into common stock of the Company at a fixed conversion price of \$2.61 per share. Upon entering the Term Note, we issued warrants to Laurus to acquire 125,000 shares of its common stock. Borrowings under the Term Note

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

were primarily used to retire the mortgage debt on our Glasgow facility. Remaining borrowings of approximately \$750,000 were used to complete the build-out of the Glasgow facility, complete the consolidation our Glasgow operations into the new facility and provide funds for operations.

In February 2004, Laurus waived the borrowing base limitation on the Credit Line, thereby making the full \$7.5 million facility available to us regardless of the available collateral. On August 31, 2004, Laurus agreed to extend the borrowing base waiver on the Credit Line through March 19, 2005. In addition, Laurus (i) deferred certain payments due under the Term Note and (ii) reduced the interest rate on both of the Laurus Loans to 0% for any day the closing sale price of our common stock is at or above \$1.75 per share.). In return, we lowered the conversion price on each of the Laurus Loans to \$1.00 per share and issued a warrant to Laurus covering an additional 400,000 common shares at an exercise price of \$1.25 per share. The closing price of our common stock on August 31, 2004 was \$1.20 per share.

Table of Contents**Analysis of Cash Flows**

Cash flows used in operating activities totaled \$8.7 million during the nine months ended September 30, 2004 compared to \$9.4 million during the comparable period of 2003. The use in 2004 related primarily to a net loss of \$27.4 million offset by non-cash charges of \$19.2 million. Non-cash charges consisted of depreciation and amortization, impairment charges, loss on debt extinguishment and non-cash financing charges. Working capital and other adjustments generated cash flows from operating activities of \$500,000.

Cash flows from investing activities totaled \$1.5 million during the nine months ended September 30, 2004 compared to cash flows used in investing activities of \$2.2 million during the comparable period of 2003. The investing cash flows generated in 2004 were from the sale of short-term investments (Geron common stock) and reductions in other assets that were offset by purchases of property and equipment.

Cash flows from financing activities totaled \$7.1 million during the nine months ended September 30, 2004 compared to \$3.2 million during the comparable period of 2003. The cash from financing activities in 2004 relate primarily to net draws on our Credit Line and proceeds from the Term Note.

Obligations and Commitments

Our ongoing capital commitments consist of debt service requirements and obligations under capital leases. The following table sets forth our contractual obligations as of September 30, 2004 along with cash payments due in each period indicated:

Amounts in Thousands	Payments Due by Period				
	2004	2005	2006	2007	2008 and Thereafter
Line of credit ¹	\$ 7,100	\$	\$	\$	\$
Long-term debt principal payments	350	850	900	650	
Operating lease payments ²	3,278	2,980	2,029	646	
Total contractual obligations	\$ 10,728	\$ 3,830	\$ 2,929	\$ 1,296	\$

1. See Note I to the condensed consolidated financial statements.
2. After giving effect to the sale of our specialty oligonucleotides manufacturing facility on November 11, 2004 (as discussed in Note L to the condensed consolidated financial statements), our ongoing operating lease payments are expected to be \$3,187, \$1,891, \$1,147, \$363 and \$0 in 2004, 2005, 2006, 2007 and thereafter.

Off Balance Sheet Arrangements

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

At September 30, 2004 and 2003, the Company did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Critical Accounting Policies

Accounting policies used in the preparation of the condensed consolidated financial statements may involve the use of management judgments and estimates. Certain of the Company's accounting policies are considered critical as they are both important to the portrayal of the Company's financial statements and they require significant or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances.

The Company considers its critical accounting policies to be:

Allowance for Doubtful Accounts

Inventories

Table of Contents

Depreciation and Amortization of Long-lived Assets

Impairment of Long-lived Assets

Revenue Recognition.

For additional discussion of these critical accounting policies, see the Management Discussion and Analysis section of the Company's 2003 Annual Report on Form 10-K.

Impact of Inflation

We do not believe that price inflation had a material adverse effect on our financial condition or results of operations during the periods presented.

Foreign Currency Rate Fluctuations

During the last three fiscal years, our international sales have represented approximately 50-65% of our net sales. These sales of products in foreign countries are mainly completed in either British Pounds Sterling or the Euro. Additionally, we have two wholly owned subsidiaries, Transgenomic, LTD., and Cruachem, LTD., whose operating currency is British Pounds Sterling and the Euro. Results of operations for the Company's foreign subsidiaries are translated using the average exchange rate during the period. Assets and liabilities are translated at the exchange rate in effect on the balance sheet dates. As a result we are subject to exchange rate risk. The operational expenses of our foreign subsidiaries help to reduce the currency exposure we have based on our sales denominated in foreign currencies by converting foreign currencies directly into goods and services. As such management feels we do not have a material exposure to foreign currency rate fluctuations at this time.

Forward-looking Information

This report contains a number of forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Many of these forward-looking statements refer to our plans, objective, expectations and intentions, as well as our future financial results. You can identify these forward-looking statements by forward-looking words such as expects, anticipates, intends, plans, may, will, believes, seeks, estimates, and similar expressions. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Such factors would include the growth of the markets for DNA analysis technology and consumable products, the acceptance of our technology, our ability to continue to improve our products, the development of competing technologies, and our ability to protect our intellectual property rights.

Controls and Procedures

Edgar Filing: TRANSGENOMIC INC - Form 10-Q/A

A review and evaluation was performed by the Company's management, including the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of the end of the period covered by this quarterly report. Based on that review and evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures, as designed and implemented, were effective. There have been no changes in the Company's internal controls subsequent to the date of their evaluation

This review and evaluation took into account the restatements described in Note M to the accompanying unaudited condensed consolidated financial statements and, after considering the nature of and the isolated effects of such restatements on the condensed consolidated statements of cash flows and the controls underlying the accumulation of the related information, the Company's management has concluded that the restatement was not the result of a material weakness in internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 6. Exhibits

(a) Exhibits

- (3.1) Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 2 to Amendment No. 1 to Registration Statement on Form S-1 (Registration No. 333-32174) as filed on May 17, 2000)
- (3.2) Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to Registration Statement on Form S1 (Registration No. 333-32174) as filed on March 10, 2000)
- (4) Form of Certificate of the Registrant's Common Stock (incorporated by reference to Exhibit 4 to Registration Statement on Form S-1 (Registration No. 333-32174) as filed on March 10, 2000)
- (10.1) Form of Securities Purchase Agreement by and between the Registrant and various counterparties dated August 27, 2003 (incorporated by reference to the Registrant's Report on Form 8-K which was filed on August 29, 2003)
- (10.2) Securities Purchase Agreement by and between the Registrant and Geron Corporation dated June 2, 2003 (incorporated by reference to Exhibit 10.0 to Amendment No. 3 to Registration Statement on Form S-3 (Registration No. 333-108319) as filed on October 14, 2003)
- (10.3) Securities Purchase Agreement by and between the Registrant and Laurus Master Fund, Ltd. dated February 19, 2004, as amended on April 15, 2004 (1)
- (10.4) Secured Convertible Term Note by and between the Registrant and Laurus Master Fund, Ltd. dated February 19, 2004, as amended on April 15, 2004 (1)
- (10.5) Common Stock Purchase Warrant by and between the Registrant and Laurus Master Fund, Ltd. dated February 19, 2004, as amended on April 15, 2004 (1)
- (10.6) Registration Rights Agreement by and between the Registrant and Laurus Master Fund, Ltd. dated February 19, 2004 (1)
- (10.7) Common Stock Purchase Warrant by and between the Registrant and TN Capital Equities, Ltd. dated March 1, 2004 (1)
- (10.8) Secured Convertible Minimum Borrowing Note Series B by and between the Registrant and Laurus Master Fund, Ltd. Dated December 3, 2003, as amended on April 15, 2004 (1)
- (10.9) Amendment No. 1 to the Employment Agreement effective March 1, 2000 by and between Transgenomic, Inc. and Collin D. Silva (incorporated by reference to the Registrant's Quarterly Report on Form 10-Q which was filed on May 17, 2004)
- (10.10) Engagement Agreement by and between the Registrant and Goldsmith, Agio, Helms Securities, Inc. dated March 19, 2004, as amended August 12, 2004 (incorporate by reference to Exhibit 10.10 to the Registrants Quarterly Report on Form 10-Q as filed on November 15, 2004)
- (10.11) Employment Agreement effective July 31, 2004 by and between Transgenomic, Inc. and Michael A. Summers (incorporate by reference to Exhibit 10.11 to the Registrants Quarterly Report on Form 10-Q as filed on November 15, 2004)
- (10.12) Amendment to securities Purchase Agreement and Related Document by and between the Registrant and Laurus Master Fund, Ltd. Dated August 31, 2004 (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-3 (Registration No. 333-118970) as filed on September 14, 2004)
- (10.13) Amendment to Security Agreement and Related Documents by and between the Registrant and laurus Master Fund, Ltd. Dated August 31, 2002 (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-3 (Registration No. 333-118970) as filed on September 14, 2004)

Table of Contents

(10.14) Common Stock Purchase Warrant by and between the Registrant and laurus Master Fund, Ltd., dated August 31, 2004 (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-3 (Registration No. 333-118970) as filed on September 14, 2004)

(31) Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

(32) Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

(1) This exhibit is incorporated by reference to the Registration Statement of the Registrant (Registration No. 333-114661), which was filed on April 21, 2004.

(b) Reports on Form 8-K

The Registrant furnished a Report on Form 8-K on August 13, 2004, reporting the announcement of its results of operations for the quarter ended June 30, 2004, pursuant to Items 5 and 12 of Form 8-K.

The Registrant filed a Report on Form 8-K on August 25, 2004, reporting the appointment of Michael A. Summers as Chief Financial Officer effective August 17, 2004 pursuant to Item 5.01 of Form 8-K.

The Registrant filed a Report on Form 8-K on September 7, 2004, reporting the amendment of its Credit Line and Term Note with Laurus Master Trust on August 31, 2004, pursuant to Item 1.01 of Form 8-K.

